Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5155267 | 0.86 | TSHR (0.33) | TSHR | |
| SCHEMBL2815843 | 0.69 | TSHR (0.38) | TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL6505047 | 0.66 | — | — | |
| Adamantane SCHEMBL29707714 | 0.66 | CYP2C9 (0.46) | TSHRLMNA | |
| Adamantane SCHEMBL12761 | 0.66 | CYP2C9 (0.46) | TSHRLMNA | |
| Adamantane SCHEMBL9016497 | 0.66 | CYP2C9 (0.46) | TSHRLMNA | |
| Adamantane SCHEMBL1527414 | 0.66 | CYP2C9 (0.46) | TSHRLMNA | |
| SCHEMBL4721541 | 0.64 | TSHR (0.40) | TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL71132 | 0.64 | TSHR (0.40) | TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL10285140 | 0.64 | TSHR (0.40) | TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9201168-B2 | Polymerizable inorganic-particle dispersant, inorganic-organic composite particles containing said polymerizable inorganic-particle dispersant, and inorganic-organic resin composite material | NIPPON KASEI CHEMICAL COMPANY LIMITED (JP) | 2015-12-01 | — | — | US | disclosed |
| US-9201168-B2 | Polymerizable inorganic-particle dispersant, inorganic-organic composite particles containing said polymerizable inorganic-particle dispersant, and inorganic-organic resin composite material | NIPPON KASEI CHEMICAL COMPANY LIMITED (JP) | 2015-12-01 | — | — | US | disclosed |
| WO-2015035234-A2 | ANTI-MICROBIAL COMPOUNDS AND COMPOSITIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-03-12 | — | — | WO | disclosed |
| EP-2762225-A1 | POLYMERIZABLE INORGANIC PARTICLE-DISPERSING AGENT, INORGANIC/ORGANIC COMPOSITE PARTICLES CONTAINING SAID POLYMERIZABLE INORGANIC PARTICLE-DISPERSING AGENT, AND INORGANIC/ORGANIC RESIN COMPOSITE | Nippon Kasei Chemical Company Limited (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-20140213725-A1 | POLYMERIZABLE INORGANIC-PARTICLE DISPERSANT, INORGANIC-ORGANIC COMPOSITE PARTICLES CONTAINING SAID POLYMERIZABLE INORGANIC-PARTICLE DISPERSANT, AND INORGANIC-ORGANIC RESIN COMPOSITE MATERIAL | NIPPON KASEI CHEMICAL COMPANY LIMITED (JP) | 2014-07-31 | — | — | US | disclosed |
| US-20140213725-A1 | POLYMERIZABLE INORGANIC-PARTICLE DISPERSANT, INORGANIC-ORGANIC COMPOSITE PARTICLES CONTAINING SAID POLYMERIZABLE INORGANIC-PARTICLE DISPERSANT, AND INORGANIC-ORGANIC RESIN COMPOSITE MATERIAL | NIPPON KASEI CHEMICAL COMPANY LIMITED (JP) | 2014-07-31 | — | — | US | disclosed |
| US-7772278-B2 | Nitrosated and nitrosylated prostaglandins, compositions and methods of use | NITROMED, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090088366-A1 | NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7449595-B2 | for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions | NITROMED, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1109542-A4 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2003086282-A2 | NITRIC OXIDE DONORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-6552047-B2 | For therapy and prophylaxis of gastrointestinal disorders; inflammations, viral infections, multiple sclerosis; decreasing the recurrence of ulcers; facilitating ulcer healing | NITROMED, INC. | 2003-04-22 | — | — | US | disclosed |
| US-20030060492-A1 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | CHIA-EN LIN. | 2003-03-27 | — | — | US | disclosed |
| US-6469065-B1 | COMPOUND THAT DONATES, TRANSFERS OR RELEASES NITRIC OXIDE, ELEVATES ENDOGENOUS LEVELS OF NITRIC OXIDE | NITROMED, INC. | 2002-10-22 | — | — | US | disclosed |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | GARVEY DAVID S (US) | 2002-10-03 | — | — | US | disclosed |
| US-20020077343-A1 | H2 RECEPTOR ANTAGONIST COMPOUNDS IN COMBINATION WITH NITRIC OXIDE DONORS, COMPOSTIONS AND METHODS OF USE | NICOX S.A. (FR) | 2002-06-20 | — | — | US | disclosed |
| EP-1154771-A1 | NITROSATED AND NITROSYLATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1109542-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000050037-A1 | NITROSATED AND NITROSYLATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000012075-A1 | NITROSATED AND NITROSYLATED ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088366-A1 | NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE | PTGIS, PGF, PTGS1 | TSHR 1884/4885KDM4E 4423/4885ALDH1A1 500/4885 |
| US-20020143007-A1 | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use | ADRB1, ADRB3, ADRA1D | TSHR 1408/4885KDM4E 2640/4885ALDH1A1 610/4885 |
| US-20030060492-A1 | Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use | HRH2, NOS2, HRH1 | TSHR 160/4885KDM4E 4246/4885ALDH1A1 3366/4885 |
| US-20020077343-A1 | H2 RECEPTOR ANTAGONIST COMPOUNDS IN COMBINATION WITH NITRIC OXIDE DONORS, COMPOSTIONS AND METHODS OF USE | HRH2, HCAR2, NOS2 | TSHR 211/4885KDM4E 4313/4885ALDH1A1 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.